Market Place
Sourcing Support
Azurity scores FDA nod for new formulation of Novartis` Tasigna
16 Nov 2024 //
FIERCE PHARMA
Novartis pays Schrödinger $150M to form drug discovery pact
13 Nov 2024 //
PR NEWSWIRE
MediciNova Faces Monetary Damages from Sanofi-Novartis Patent
11 Nov 2024 //
GLOBENEWSWIRE
Novartis filed patent lawsuits in defense of radiopharma meds
04 Nov 2024 //
FIERCE PHARMA
Novartis CEO `very confident` on sales target, doesn`t fear patent cliff
04 Nov 2024 //
REUTERS
Novartis` $2.9B MorphoSys bet stumbles as safety delays filing
30 Oct 2024 //
FIERCE BIOTECH
Novartis` Scemblix leaps into newly diagnosed CML
30 Oct 2024 //
FIERCE PHARMA
Novartis complies with FDA `flexibility` ask in Pluvicto filing
29 Oct 2024 //
FIERCE PHARMA
Novartis Explores Obesity Drugs While Focusing on Growth Areas
29 Oct 2024 //
REUTERS
Novartis Raises Yearly Outlook Despite Disappointing Pluvicto
29 Oct 2024 //
REUTERS
Novartis Reports Q3 Sales Growth and Raises FY 2024 Guidance
29 Oct 2024 //
GLOBENEWSWIRE
Novartis Scemblix® Approved for Newly Diagnosed CML
29 Oct 2024 //
GLOBENEWSWIRE
Novartis Inks $2.2B Molecular Glue Deal With Monte Rosa"
29 Oct 2024 //
REUTERS
Novartis, Apellis roll out rival datasets in rare kidney disease
28 Oct 2024 //
FIERCE PHARMA
Novartis’ Fabhalta® Maintains Results in C3G Phase III Trial
26 Oct 2024 //
GLOBENEWSWIRE
Novartis Ribociclib (Kisqali®) Receives NCCN Category 1 Status
24 Oct 2024 //
GLOBENEWSWIRE
Novartis ribociclib recognized as Category 1 preferred breast cancer treatment
24 Oct 2024 //
GLOBENEWSWIRE
Judge upholds MSN`s generic Entresto nod amid Novartis challenge
19 Oct 2024 //
FIERCE PHARMA
Novartis Gets Positive CHMP Opinion For Kisqali® In Breast Cancer
18 Oct 2024 //
GLOBENEWSWIRE
Novartis loses latest bid to block generic version of blockbuster heart drug
17 Oct 2024 //
REUTERS
Novartis pays Baiyu $70M, with $1.1B chaser, for cancer prospect
17 Oct 2024 //
FIERCE BIOTECH
PE firms queue up for Novartis` Indian arm
12 Oct 2024 //
ECONOMICTIMES
Swiss Authority Closes Novartis Probe Without Consequences
10 Oct 2024 //
REUTERS
Novartis`s Biologic Cosentyx (Secukinumab) Receives Approval in US
04 Oct 2024 //
FDA
Novartis inks $1B-plus biobucks deal with Flagship`s Generate
25 Sep 2024 //
BIOSPACE
Firefly Advances AI-Driven BNA™ Technology in Neuroscience
20 Sep 2024 //
GLOBENEWSWIRE
Novartis Gets Broad FDA Approval For Kisqali In Early Breast Cancer
18 Sep 2024 //
PR NEWSWIRE
PanTera Attracts $102.5M In Series A For Radiopharmaceutical Manufacturing
12 Sep 2024 //
ENDPTS
Relay Therapeutics` Combo Cuts Breast Cancer Progression In Early Study
10 Sep 2024 //
REUTERS
Despite trial scare, Travere`s IgAN drug wins full FDA approval
06 Sep 2024 //
FIERCE PHARMA
Novartis ignites new stage of Voyager pact with $15M capsid deal
05 Sep 2024 //
FIERCE BIOTECH
Novartis Begins Construction of New Radioligand Therapy Facilities in the US
05 Sep 2024 //
PR NEWSWIRE
Novartis brings blood cancer sculptures to Scotland, symptom awareness
02 Sep 2024 //
FIERCE PHARMA
Novartis` Leqvio Shows Promise in Lowering Cholesterol
29 Aug 2024 //
CONTRACT PHARMA
With phase 3 win, Novartis pads case for broader use of heart med Leqvio
28 Aug 2024 //
FIERCE PHARMA
Novartis To Spend $1B On New Biologics Formulations
28 Aug 2024 //
FIERCE PHARMA
Novartis Twice-Yearly Leqvio Demonstrated Clinically Meaningful LDL-C Lowering
28 Aug 2024 //
GLOBENEWSWIRE
Versant’s Jerel Davis on build-to-buy deals and pharma investment
26 Aug 2024 //
BIOPHARMADIVE
Siemens Healthineers To Acquire Novartis` European Radiodiagnostic Network
26 Aug 2024 //
FIERCE BIOTECH
Novartis Receives Offer From Siemens Healthineers For Molecular Imaging Unit
24 Aug 2024 //
REUTERS
Novartis and Versant Partner to Form Kidney Disease Biotech
23 Aug 2024 //
BIOSPACE
Novartis loses initial bid to block generic of best-selling heart drug
13 Aug 2024 //
REUTERS
Immunic Reports Q2 2024 Results And Provides Corporate Update
08 Aug 2024 //
PR NEWSWIRE
US FDA Approves Novartis` Kidney Disease Drug
08 Aug 2024 //
REUTERS
Novartis, Viatris face new lawsuit over `HeLa` cell misuse claims
06 Aug 2024 //
REUTERS
Novartis Files FDA Complaint In Entresto Patent Defense
01 Aug 2024 //
FIERCE PHARMA
Biogen lifts profit forecast, signals progress in turnaround effort
01 Aug 2024 //
REUTERS
US court finds ‘robust’ anti-fraud safeguards in Novartis settlement
29 Jul 2024 //
REUTERS
Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal
25 Jul 2024 //
FIERCE BIOTECH
Dren Bio And Novartis Partner On Cancer Myeloid Engagers
24 Jul 2024 //
BUSINESSWIRE
Novartis taps Dren Bio in $3B pact focused on myeloid engagers
24 Jul 2024 //
ENDPTS
Drug giants eye China for deals despite growing Sino-US tensions
23 Jul 2024 //
REUTERS
‘Not prudent’ for Novartis to join GLP-1 obesity race as late-runner, says CEO
19 Jul 2024 //
FIERCE BIOTECH
Novartis CEO: IRA Impact Manageable, Maintains Midterm Growth Goal
19 Jul 2024 //
FIERCE PHARMA
Novartis Reports Strong Q2 Growth And Raises 2024 Guidance
18 Jul 2024 //
GLOBENEWSWIRE
Novartis raises 2024 profit guidance for second time
18 Jul 2024 //
REUTERS
US FDA to ban use of brominated vegetable oil in food, soda
03 Jul 2024 //
REUTERS
As former BMS CEO Giovanni Caforio plots move to Novartis
01 Jul 2024 //
FIERCE PHARMA
Pfizer poaches Novartis exec for oncology commercial chief post
29 Jun 2024 //
FIERCE PHARMA
Novartis Pharms Corp Biologic Crizanlizumab-Tmca Receives Approval in US
26 Jun 2024 //
FDA
